Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022
Evofem Biosciences (EVFM) will conduct an investor call on Thursday, August 11, 2022, at 5:00 p.m. ET. The call will focus on the company's developments in women's sexual and reproductive health, particularly regarding their FDA-approved product, Phexxi®. Phexxi is a hormone-free vaginal gel contraceptive. The company anticipates releasing top-line data in October 2022 from its Phase 3 EVOGUARD clinical trial, which studies Phexxi for preventing chlamydia and gonorrhea. Details for joining the call are available in the press release.
- None.
- None.
-- Conference Call Scheduled for 5:00 p.m. ET --
SAN DIEGO, Aug. 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows:
Date: | Thursday, August 11, 2022 |
Time: | 5:00 p.m. ET (2:00 p.m. PT) |
Live call: | (877) 445-9755 (U.S. toll-free) or (201) 493-6744 |
Webcast (live and archived): | https://evofem.investorroom.com/Update or |
Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 15 minutes prior to the start of the call.
About Evofem Biosciences
Evofem Biosciences, Inc., (EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. The Company expects to report top-line data in October 2022 from its registrational Phase 3 EVOGUARD clinical trial evaluating Phexxi for two potential new indications – prevention of chlamydia and prevention of gonorrhea in women. Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-host-investor-call-on-thursday-august-11-2022-301603911.html
SOURCE Evofem Biosciences, Inc.
FAQ
What is the date of the Evofem Biosciences investor call?
What time is the Evofem investor call?
How can I join the Evofem Biosciences investor call?
What product is Evofem Biosciences known for?
When will Evofem report data from the EVOGUARD trial?
